Olokizumab

Olokizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	IL6
Clinical data
ATC code	none;
Identifiers
CAS Number	1007223-17-7 ;
ChemSpider	none;
UNII	PAI71R1D2W;
(what is this?) (verify)

Olokizumab is an immunomodulator. It binds to interleukin 6.[1] Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA).

It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe whan.[2][3]

References

World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
Another IL-6 Blocker in RA
Genovese, MC (2014). "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204760. PMC 4145439. Retrieved 21 February 2016.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.

[2] Another IL-6 Blocker in RA

[3] Genovese, MC (2014). "Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study". Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204760. PMC 4145439. Retrieved 21 February 2016.